Sanofi — Regulatory Filings 2021

Dec 16, 2021

==> picture [136 x 41] intentionally omitted <==

Pres Release XTA)UROanfi (E: urce So

SDQ

: SNY)

PARIS – Decmbr 16,20 On D r1 cmb ,2 0thBadf s a ireto nd es Schne, an ipt di nde ecto of Sanofi, as Chirmn of the Ames, nt oi Govac and CSR Co. Gies Schne lavs his ptn on the Audit This ame foi ws S ol rg Winbrg's decson to step down as Chirmn of the s, Gvr ntpo cdSRo mite , ashw lno rbaipt nd h grup, rvicn thB s oer , to nDmb irec Afp in ac ord f Co. ed rgWinbAs S g,hs03Grl M t2 dof a hen cw ofite decson wi also nabl the Group to cotiue eaing his pr eion in the best poible way. About Sanfi i sdectuprglhano robi phm ale s. W an y f comhlt .W prvn ies wh vti mnsfgh ain es rg.W t andby hefwo saedi nthlo swing term hroni cts. With more than 1, ol in 1 countries, Sanofi is tsfomig sentf ci inoat helrsu dgb. Media RltonsCc Sa nd ol Tel.: +)6 25 914 andie.uo l@sfcm r@sanfi.c

Investor RlaiCcP SchEvfr Jase aud DArlpi lie Pm Investor RlaiCc North Ameica lix Lauschr Tel.: +(0)1 574 inestor. @fcm /w.anoic vr

Sanofi Frw rd Loking Staems tfwrd onreis e.sn5,Act1 ef n RScusLg atri f h stae wad ki staemrhn is lf.T at tsade ro mh derlyg un o, asmen rg adiplan s, o vi ti bjs e ionswih rxpc spct to ftre fcl ult, re vnts, peratins, rvic, product d se vlopmnt and poenial, and s s adin ftre pfomanc. Fo er wad king statements are generally identified by the words —expects“, —anticmilar expressions. Although Sanofi‘s management bewadctd insuch fo sonb, eal stae ki ieves that the expectati estor a cuhfo g f rmatseu bjc toaris d u,myofw ce i are difclto h cr et fSa t fi, acouldsern vpty ifa from tho se exprsdin, or mpled or projctdby, the fowad in kingfrmatad st mn.Th rikad unc clude amer ings, th e she t ich rende , fvlopm a dcli an lsi cudg post eting, dcsowp EM vic filmy bon h capt r b mas er ado n n regailei as th es ni dt hpro uc d forany s tesf apucnpro cta s, ni dta h pro uc nfs otorcmeial by afet ould a c ved mayntpr c beyseria uccessful, the future approval and commercial success of th nal g tr whes, un let ra cmp o atns cid/ re gu, red woc as hn cua tel ro grtes ndxchds i,rgao it efsuh l o li eu d an e l utor diglt p y ande prevalng ters a ,v olecnm adtconis rk taein vd su qc ha ro, t ndheimpac ha COVID 19 w ilhaveonus,rctpd i ayoe coCOVID f ri te sw.Any al d t he urp lnasem f th 19 thay on notu whcr aehn cagrdlitom .T ptyicould as wrently a and yetoh xc ius lfpv. T andcetl soiu isde uncr of in the public filings with the SEC and the AMF made by Sanofi, inclumn te in Fow gard Re Looking Statements“ in Sanofi‘s annual report on Form 20F for nser th . ODcmb31, 20 ya e th vsny fowd aer upd t blur tdeno cw,S apl b qu re rmatse g f